Gemcitabine for the treatment of advanced nonsmall cell lung cancer

by Toschi, Luca, Cappuzzo, Federico
Published 2009

Optimal front line treatment for European patients harboring EGFR mutations: Do longitude and race make a difference?

by Landi, Lorenza, Cappuzzo, Federico
Published 2012

Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer

by Stasi, Irene, Cappuzzo, Federico
Published 2014

Writing in PROSE proteomic-based selection for second line treatment in non-small-cell lung cancer

by Landi, Lorenza, Cappuzzo, Federico
Published in Ann Transl Med (2015)

EGFR TKIs as maintenance therapy in NSCLC: Finding the old in the new INFORMation

by Landi, Lorenza, Cappuzzo, Federico
Published in Transl Lung Cancer Res (2012)

Targeting MET in NSCLC: looking for a needle in a haystack

by Landi, Lorenza, Cappuzzo, Federico
Published in Transl Lung Cancer Res (2014)

Irreversible EGFR-TKIs: dreaming perfection

by Landi, Lorenza, Cappuzzo, Federico
Published in Transl Lung Cancer Res (2013)

Immunotherapy and lung cancer: from therapeutic cancer vaccination to novel approaches

by Mazza, Valentina, Cappuzzo, Federico
Published in J Thorac Dis (2016)

Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer

by Stasi, Irene, Cappuzzo, Federico
Published in Lung Cancer (Auckl) (2014)

Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLC

by Landi, Lorenza, Cappuzzo, Federico
Published in Transl Lung Cancer Res (2016)

Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinib

by Mazza, Valentina, Cappuzzo, Federico
Published in Appl Clin Genet (2017)

A few pills twice a day keep ALK-positive non-small-cell lung cancer at bay

by Landi, Lorenza, Cappuzzo, Federico
Published in J Thorac Dis (2017)

How selecting best upfront therapy for metastatic disease?—Focus on ROS1-rearranged disease

by Landi, Lorenza, Cappuzzo, Federico
Published in Transl Lung Cancer Res (2020)

Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer

by D’Arcangelo, Manolo, Cappuzzo, Federico
Published 2013

K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value

by D'Arcangelo, Manolo, Cappuzzo, Federico
Published in ISRN Mol Biol (2012)

Lung Cancer Update 2017: from the test tube to the bed

by Bertolaccini, Luca, Cappuzzo, Federico, Solli, Piergiorgio
Published in Ann Transl Med (2018)

Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung ca...

by Romanidou, Ourania, Landi, Lorenza, Cappuzzo, Federico, Califano, Raffaele
Published in Ther Adv Med Oncol (2016)

Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR...

by Osarogiagbon, Raymond U., Cappuzzo, Federico, Ciuleanu, Tudor, Leon, Larry, Klughammer, Barbara
Published in Transl Lung Cancer Res (2015)

MET overexpression and gene amplification in NSCLC: a clinical perspective

by Landi, Lorenza, Minuti, Gabriele, D’Incecco, Armida, Salvini, Jessica, Cappuzzo, Federico
Published in Lung Cancer (Auckl) (2013)

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

by Drilon, Alexander, Cappuzzo, Federico, Ou, Sai-Hong Ignatius, Camidge, D. Ross
Published in J Thorac Oncol (2016)